ERBB2 and breast cancer: Nevertheless, 10–30% of women with early-stage, estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer will experience locoregional or distant recurrence, with approximately half of these events arising more than 5 years after the initial diagnosis [7].